Kintsugi is a private healthcare AI company that uses voice biomarkers to help detect depression and anxiety. Its enterprise platform supports clinical decision-making across call centers, telehealth, and remote monitoring workflows.
UpMarket does not offer Kintsugi shares. This page covers the history of Kintsugi before it shut down.
How to Review the Funding History of Kintsugi on UpMarket
Kintsugi ceased operations on February 11, 2026. UpMarket does not offer Kintsugi shares. This page covers its earlier valuation and funding history.
Step 01
Check the company's status
Kintsugi ceased operations on February 11, 2026.
Step 02
Review the valuation history
See how the private-market valuation of Kintsugi changed across funding rounds before it shut down.
Step 03
Review funding and revenue data
See reported funding rounds and revenue figures on this page, with their sources.
Step 04
Explore private companies
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
May 30, 2024
Series A
Seed
Seed
Seed
Kintsugi Revenue and Growth
Annual revenue
Why Investors Are Watching Kintsugi
Growth Signal
Kintsugi raised at least $30M to scale AI tax automation
Clay reports Kintsugi has raised at least $30 million across four disclosed funding rounds and was valued at $150 million. The company is positioned to expand its AI-driven sales tax automation platform globally.
Product Milestone
KiVA voice biomarker API targets clinical mental health scoring
Insight Partners says Kintsugi's KiVA platform provides real-time mental health scoring through voice biomarkers and integrates with clinical call centers, telehealth platforms, and remote patient monitoring apps. The company says its models are language-agnostic because they analyze how patients speak rather than natural language content.
Market Opportunity
Kintsugi says its tech could reach millions of patient calls
Fierce Healthcare reported Kintsugi was already being adopted by healthcare organizations and was on track to be used on millions of patient phone calls by the end of 2022. The company said its AI helps clinicians detect depression and anxiety faster using short clips of speech.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. Kintsugi ceased operations on February 11, 2026 and has no tradable shares. UpMarket does not offer Kintsugi shares.
Kintsugi has no stock price and no current valuation. The figures on this page are historical private-market valuations from before it shut down.
No. Kintsugi has shut down, and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Kintsugi has ceased operations. This page is kept for its historical funding and valuation data. UpMarket does not offer Kintsugi shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Kintsugi ceased operations on February 11, 2026. What former shareholders receive, if anything, depends on the company's wind-down or dissolution.
UpMarket does not offer Kintsugi shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
UpMarket does not publish an estimate for Kintsugi. The figures on this page show its valuation history before it shut down.
Kintsugi uses voice biomarkers to help detect depression and anxiety through its enterprise healthcare AI platform, generating $20M in 2024 revenue, and has raised at least $30M to scale its AI capabilities. Kintsugi has ceased operations, and UpMarket does not offer its shares.